Sanofi to shut­ter ex-Kymab R&D fa­cil­i­ty in the UK

Sanofi is clos­ing an ex-Kymab re­search and de­vel­op­ment site in Cam­bridge, UK, which could see job loss­es for 90 staffers, a com­pa­ny spokesper­son told End­points News. 

“Up­on care­ful re­view of our R&D glob­al foot­print, we are propos­ing to end re­search op­er­a­tions in Cam­bridge, UK, a site which joined our com­pa­ny through ac­qui­si­tion in 2021,” the spokesper­son said in an email. Sanofi bought mon­o­clon­al an­ti­body de­vel­op­er Kymab for $1.45 bil­lion in April 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER